Roche Holding Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis